Hodgkins lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Engert, A ^a,b   Eichenauer, D A ^a,b   Dreyling, M ^c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b German Hodgkin Study Group (GHSG)   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; NAVELBINE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CLASSICAL HODGKIN LYMPHOMA; CLINICAL PRACTICE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA; MIXED CELLULARITY HODGKIN LYMPHOMA; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; SALVAGE THERAPY; UNSPECIFIED SIDE EFFECT; EARLY DIAGNOSIS; EUROPE; HEART FUNCTION TEST; INCIDENCE; LUNG FUNCTION TEST; LYMPH NODE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOTHERAPY; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; EARLY DETECTION OF CANCER; EUROPE; FOLLOW-UP STUDIES; HEART FUNCTION TESTS; HODGKIN DISEASE; HUMANS; INCIDENCE; LYMPH NODES; NEOPLASM STAGING; RADIOTHERAPY; RECURRENCE; REMISSION INDUCTION; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 77954334903     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq181     Document Type: Article

References (17)

1. Engert A, Franklin J, Eich HT et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007; 25: 3495-3502.
2. Ferme C, Eghbali H, Meerwaldt JH et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357: 1916-1927.
3. Borchmann P, Engert A, Pluetschow A et al. Dose-intensified combined modality treatment with 2 cycles of BEACOPPescalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IF-RT in patients with early unfavourable Hodgkin Lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood 2008 (ASH Annual Meeting Abstracts); 112: Abstr 367.
4. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-2071.
5. Morschhauser F, Brice P, Ferme C et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/ refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008; 26: 5980-5987.
6. Josting A, Rudolph C, Reiser M et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002; 13: 1628-1635.
7. Santoro A, Magagnoli M, Spina M et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007; 92: 35-41.
8. Sieniawski M, Franklin J, Nogova L et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007; 25: 2000-2005.
9. Josting A, Nogova L, Franklin J et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005; 23: 1522-1529.
10. Sureda A, Robinson S, Canals C et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455-462.
11. Peggs KS, Hunter A, Chopra R et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 1934-1941.
12. Ekstrand BC, Lucas JB, Horwitz SM et al. Rituximab in lymphocytepredominant Hodgkin disease: results of a phase 2 trial. Blood 2003; 101: 4285-4289.
13. Schulz H, Rehwald U, Morschhauser F et al. Rituximab in relapsed lymphocytepredominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111: 109-111.
14. Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-59.
15. Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fluoro-2-deoxy-Dglucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752.
16. Kobe C, Dietlein M, Franklin J et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112: 3989-3994.
17. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.